CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma
Laurence Albiges, Manuela Schmidinger, Naila Taguieva-Pioger, David Perol, Viktor Grünwald, Eric Guemas, Laurence Albiges, Manuela Schmidinger, Naila Taguieva-Pioger, David Perol, Viktor Grünwald, Eric Guemas
Abstract
Cabozantinib is an inhibitor of multiple tyrosine kinases, including AXL, MET and VEGF receptors. Here, we describe the rationale and design for the phase II CaboPoint trial (ClinicalTrials.gov identifier: NCT03945773), which will evaluate the efficacy and safety of cabozantinib as a second-line treatment in patients with unresectable, locally advanced or metastatic renal cell carcinoma whose disease has progressed despite checkpoint inhibitor therapy. Patients will be recruited into two cohorts: prior ipilimumab plus nivolumab (cohort A) or prior checkpoint inhibitor-VEGF-targeted therapy (cohort B). All patients will receive once-daily oral cabozantinib 60 mg for up to 18 months. The primary end point is objective response rate. Secondary end points include overall survival, progression-free survival and safety.
Keywords: cabozantinib; checkpoint inhibitor; renal cell carcinoma; second line; tyrosine kinase inhibitor.
Source: PubMed